Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innate CNS Immune Response in Fibromyalgia
NCT04263454Phase 3Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 3, open-label trial (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Change in Ratio of Choline/Creatine in the Brain at 3 hours, Change in Ratio of Myoinositol/Creatine in the Brain at 3 hours and 1 more. Started Mar 2020; status: completed.
Beyond the preview
Go deeper on NCT04263454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263454.